+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cadonilimab Injection Market - Global Forecast 2025-2030- Product Image
Cadonilimab Injection Market - Global Forecast 2025-2030- Product Image
Sale

Cadonilimab Injection Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6129618
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cadonilimab injection market is undergoing significant transformation, with rapid advancements in bispecific antibody technology propelling innovative therapies to the forefront of the immuno-oncology sector. Amid complex global dynamics and rising demand for targeted biologics, strategic leaders require robust, actionable intelligence to navigate the evolving competitive environment.

Market Snapshot: Cadonilimab Injection Market

The Cadonilimab injection market is set to expand, driven by increasing cancer incidence, strong regulatory momentum, and continued investment in immuno-oncology. Following recent clinical validation and regulatory milestones, the market demonstrates a strong trajectory, underpinned by growing adoption in major healthcare markets and early real-world evidence generation. Heightened interest from payers and policymakers is further fostering investment and uptake, as precision oncology and personalized medicine become strategic priorities for health systems worldwide.

Scope & Segmentation

  • Indications: Cervical cancer (metastatic, recurrent), gastric cancer (advanced, metastatic), hepatocellular carcinoma (advanced, compensated cirrhosis), non-small cell lung cancer (Stage III, Stage IV)
  • Treatment Lines: First, second, and third line applications, reflecting diverse pathways and clinical strategies
  • Distribution Channels: Hospital pharmacy, online pharmacy, retail pharmacy
  • End Users: Hospitals, clinics, and ambulatory surgical centers each presenting specific purchase cycles and clinical integration
  • Dosage Strengths: 150 mg, 300 mg, and 450 mg formats for flexible dosing protocols
  • Patient Demographics: Adult, elderly, and pediatric cohorts, supporting broad-spectrum safety and efficacy assessment
  • Regions: Americas (United States including California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada; Mexico; Brazil; Argentina), Europe, Middle East & Africa (including the United Kingdom, Germany, France, and select markets), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Technologies: Bispecific antibody engineering, continuous bioprocessing, automated cell culture, remote patient monitoring, and digital real-time safety reporting
  • Key Companies Analyzed: Suzhou Akeso Biopharmaceutical Co., Ltd.

Key Takeaways for Senior Decision-Makers

  • Bispecific antibodies are reshaping immuno-oncology, with Cadonilimab targeting dual immune checkpoints for enhanced clinical outcomes.
  • Real-world evidence from leading academic centers is accelerating broader acceptance, informing reimbursement, and driving health technology assessment initiatives.
  • Market entry strategies must address region-specific regulatory frameworks, reimbursement timing, infrastructure capabilities, and local manufacturing requirements.
  • Strategic partnerships spanning clinical development, manufacturing, and distribution will be essential to mitigate risks and support scaling as demand increases.
  • Stakeholder engagement—especially with payers and clinicians—is critical to facilitate outcomes-based pricing and ensure sustained access across diverse markets.

Primary Keyword: Cadonilimab Injection—Tariff Impact and Supply Chain Dynamics

Evaluating Tariff Adjustments in the United States

Recent tariff adjustments in the United States have increased input costs for biopharmaceutical manufacturing, influencing the Cadonilimab injection market. Extended lead times for key ingredients and excipients have prompted manufacturers to implement inventory buffers and diversify sourcing strategies. In response, some supply chain participants are localizing production, while others utilize digital supply platforms and predictive analytics to optimize procurement and inventory. Enhanced regulatory scrutiny over imports adds to both complexity and operational risk. Effective navigation of these dynamics is vital for maintaining market access and securing patient care continuity.

Methodology & Data Sources

This analysis integrates primary interviews with industry experts, oncologists, and reimbursement professionals. Primary findings are cross-referenced with quantitative data from peer-reviewed journals, regulatory submissions, government publications, and clinical registries. A dedicated expert review panel ensures findings are validated and actionable. Data collection and analysis comply with stringent ethical standards and confidentiality protocols.

Why This Report Matters

  • Enables senior executives to assess emerging market opportunities and anticipate regulatory shifts with confidence.
  • Guides informed investment by highlighting robust segmentation, evidence-based adoption drivers, and region-specific considerations.
  • Supports strategic planning by offering clear, actionable recommendations aligned with evolving industry best practices.

Conclusion

The Cadonilimab injection market exemplifies the convergence of breakthrough science and market innovation. A deliberate, data-driven approach will position decision-makers to capture value, build resilient operations, and enhance patient outcomes in this dynamic landscape.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Recent phase III trial results demonstrating superior overall survival in advanced gastric cancer patients
5.2. Emerging market approvals and reimbursement challenges for cadonilimab injection in Asia-Pacific countries
5.3. Comparative efficacy and safety analysis of cadonilimab versus standard PD-1 monotherapy in head and neck cancer
5.4. Integration of PD-L1 biomarker screening to optimize patient selection and response rates in clinical practice
5.5. Expanding combination regimens with chemotherapy and antiangiogenic agents to enhance cadonilimab efficacy
5.6. Real-world safety monitoring and management of immune-related adverse events in routine oncology settings
5.7. Scale-up of manufacturing capabilities and supply chain strategies to meet growing global cadonilimab demand
5.8. Competitive landscape assessment of bispecific PD-1/CTLA-4 inhibitors and next-generation immunotherapies
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cadonilimab Injection Market, by Indication
8.1. Introduction
8.2. Cervical Cancer
8.2.1. Metastatic
8.2.2. Recurrent
8.3. Gastric Cancer
8.3.1. Advanced
8.3.2. Metastatic
8.4. Hepatocellular Carcinoma
8.4.1. Advanced
8.4.2. Compensated Cirrhosis
8.5. Non Small Cell Lung Cancer
8.5.1. Stage Iii
8.5.2. Stage Iv
9. Cadonilimab Injection Market, by Treatment Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line
10. Cadonilimab Injection Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Cadonilimab Injection Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.4. Hospitals
12. Cadonilimab Injection Market, by Dosage Strength
12.1. Introduction
12.2. 150 Mg
12.3. 300 Mg
12.4. 450 Mg
13. Cadonilimab Injection Market, by Patient Demographics
13.1. Introduction
13.2. Adults
13.3. Elderly
13.4. Pediatric
14. Americas Cadonilimab Injection Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Cadonilimab Injection Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Cadonilimab Injection Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Suzhou Akeso Biopharmaceutical Co., Ltd.
18. ResearchAI19. ResearchStatistics20. ResearchContacts21. ResearchArticles22. Appendix
List of Figures
FIGURE 1. CADONILIMAB INJECTION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CADONILIMAB INJECTION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CADONILIMAB INJECTION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CADONILIMAB INJECTION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. CADONILIMAB INJECTION MARKET: RESEARCHAI
FIGURE 28. CADONILIMAB INJECTION MARKET: RESEARCHSTATISTICS
FIGURE 29. CADONILIMAB INJECTION MARKET: RESEARCHCONTACTS
FIGURE 30. CADONILIMAB INJECTION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CADONILIMAB INJECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CADONILIMAB INJECTION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CADONILIMAB INJECTION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY METASTATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY METASTATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY RECURRENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY RECURRENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY ADVANCED, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY ADVANCED, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY METASTATIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY METASTATIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY ADVANCED, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY ADVANCED, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY COMPENSATED CIRRHOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY COMPENSATED CIRRHOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY STAGE III, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY STAGE III, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY STAGE IV, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY STAGE IV, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY 150 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY 150 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY 300 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY 300 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY 450 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY 450 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY ADULTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY ELDERLY, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL CADONILIMAB INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES CADONILIMAB INJECTION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 127. CANADA CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 130. CANADA CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 131. CANADA CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 132. CANADA CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 133. CANADA CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 134. CANADA CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 135. CANADA CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 136. CANADA CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 137. CANADA CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 138. CANADA CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 139. CANADA CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 140. CANADA CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 141. CANADA CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 142. CANADA CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 143. CANADA CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 144. CANADA CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 145. CANADA CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 146. CANADA CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 147. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 150. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 151. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 152. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 153. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 154. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 155. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 156. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 157. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 158. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 159. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 164. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 165. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA CADONILIMAB INJECTION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 249. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 252. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 253. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 254. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 255. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 256. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 257. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 258. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 259. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 260. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 261. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 264. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 265. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 266. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 267. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 268. GERMANY CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 269. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 270. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 271. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 272. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 273. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 274. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 275. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 276. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 277. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 278. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 279. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 280. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 281. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 282. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 283. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 286. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 287. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 288. FRANCE CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 299. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 300. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 301. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 306. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 307. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 308. RUSSIA CADONILIMAB INJECTION MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 309. ITALY CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. ITALY CADONILIMAB INJECTION MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 311. ITALY CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2018-2024 (USD MILLION)
TABLE 312. ITALY CADONILIMAB INJECTION MARKET SIZE, BY CERVICAL CANCER, 2025-2030 (USD MILLION)
TABLE 313. ITALY CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2018-2024 (USD MILLION)
TABLE 314. ITALY CADONILIMAB INJECTION MARKET SIZE, BY GASTRIC CANCER, 2025-2030 (USD MILLION)
TABLE 315. ITALY CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2018-2024 (USD MILLION)
TABLE 316. ITALY CADONILIMAB INJECTION MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, 2025-2030 (USD MILLION)
TABLE 317. ITALY CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 318. ITALY CADONILIMAB INJECTION MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 319. ITALY CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 320. ITALY CADONILIMAB INJECTION MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 321. ITALY CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 322. ITALY CADONILIMAB INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 323. ITALY CADONILIMAB INJECTION MARKET SIZE, BY END USER, 2018-2024 (USD

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Cadonilimab Injection Market report include:
  • Suzhou Akeso Biopharmaceutical Co., Ltd.

Related Topics

Related Reports

Mitomycin for Injection Market - Global Forecast to 2030 - Product Image

Mitomycin for Injection Market - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Ipilimumab Injection Market - Global Forecast 2025-2030 - Product Image

Ipilimumab Injection Market - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Self-injection Devices Market Size, Share & Trends Analysis By Product (Auto Injectors, Pen Injectors), By Usability (Disposable, Reusable), By Application (Cancer, Autoimmune Disorders, Hormonal Disorders), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Self-injection Devices Market Size, Share & Trends Analysis By Product (Auto Injectors, Pen Injectors), By Usability (Disposable, Reusable), By Application (Cancer, Autoimmune Disorders, Hormonal Disorders), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Anti-Tumor Injection Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Anti-Tumor Injection Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 110 Pages
  • Global
From
Injection Pen Market Size, Share & Trends Analysis Report By Product (Disposable, Reusable), By Application (Osteoporosis, Diabetes, Anaphylaxis), By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Injection Pen Market Size, Share & Trends Analysis Report By Product (Disposable, Reusable), By Application (Osteoporosis, Diabetes, Anaphylaxis), By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 170 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.